ArticlePortal hypertension & cirrhosis2025

Resmetirom and thyroid hormone receptor-targeted treatment for metabolic dysfunction-associated steatotic liver disease (MASLD).

Chang-Hai Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.